The most frequent grade @ or worse toxicities were hypertension ( @ -LSB- @ % -RSB- of @ patients in the bevacizumab group , three -LSB- @ % -RSB- of @ in the lomustine group , and @ -LSB- @ % -RSB- of @ in the bevacizumab and lomustine @ mg/m ( @ ) group ) , fatigue ( two -LSB- @ % -RSB- , four -LSB- @ % -RSB- , and eight -LSB- @ % -RSB- ) , and infections ( three -LSB- @ % -RSB- , two -LSB- @ % -RSB- , and five -LSB- @ % -RSB- ) .